CorriXR Therapeutics

CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology.

CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not the genome of a healthy cell thereby conferring target selectivity. It is uniquely directed towards knocking out genetic pathways to allow for a broad-based combinatorial therapeutic regimen for the treatment of solid tumors.

The company’s initial genetic pathway target is the NRF2 gene. The Nrf2 protein is a global transcriptional regulator that functions to activate genes in response to cellular stress and is implicated in progression of solid tumors. CorriXR’s objective is to use CRISPR-directed gene editing to disable NRF2 gene functions specifically in cancer cells. The company says preclinical data in both cell and animal models confirms that the NRF2 gene is a viable target for a gene editing therapeutic for solid tumors.

CorriXR Therapeutics is the inaugural biotech spin-out of ChristianaCare, a large healthcare system, and the Gene Editing Institute (GEI), which has been embedded in ChristianaCare’s Helen F. Graham Cancer Center & Research Institute since 2015.

Subscribe for alerts on new companies featured on Startups.Bio

Archon Biosciences
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Cytospire Therapeutics
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
This Week in Biotech Venture Capital
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …

View all recently featured startups

Tags: